HRP20010667B1 - Camptothecin derivatives having antitumor activity - Google Patents

Camptothecin derivatives having antitumor activity

Info

Publication number
HRP20010667B1
HRP20010667B1 HR960321A HRP20010667A HRP20010667B1 HR P20010667 B1 HRP20010667 B1 HR P20010667B1 HR 960321 A HR960321 A HR 960321A HR P20010667 A HRP20010667 A HR P20010667A HR P20010667 B1 HRP20010667 B1 HR P20010667B1
Authority
HR
Croatia
Prior art keywords
antitumor activity
camptothecin derivatives
camptothecin
derivatives
antitumor
Prior art date
Application number
HR960321A
Other languages
English (en)
Inventor
Sergio Penco
Lucio Merlini
Franco Zunino
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Ist Naz Stud Cura Dei Tumori filed Critical Sigma Tau Ind Farmaceuti
Publication of HRP20010667A2 publication Critical patent/HRP20010667A2/hr
Publication of HRP20010667B1 publication Critical patent/HRP20010667B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR960321A 1999-03-09 2001-09-10 Camptothecin derivatives having antitumor activity HRP20010667B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity
PCT/EP2000/001570 WO2000053607A1 (en) 1999-03-09 2000-03-08 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
HRP20010667A2 HRP20010667A2 (en) 2002-08-31
HRP20010667B1 true HRP20010667B1 (en) 2003-06-30

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960321A HRP20010667B1 (en) 1999-03-09 2001-09-10 Camptothecin derivatives having antitumor activity

Country Status (39)

Country Link
US (2) US6242457B1 (xx)
EP (1) EP1044977B1 (xx)
JP (1) JP4610743B2 (xx)
KR (1) KR100702085B1 (xx)
CN (1) CN1139592C (xx)
AR (1) AR022860A1 (xx)
AT (1) ATE216998T1 (xx)
AU (1) AU774174B2 (xx)
BG (1) BG65032B1 (xx)
BR (1) BR0008840B1 (xx)
CA (1) CA2362760C (xx)
CO (1) CO5180590A1 (xx)
CZ (1) CZ304465B6 (xx)
DE (1) DE69901379T2 (xx)
DK (1) DK1044977T3 (xx)
EA (1) EA003605B1 (xx)
EE (1) EE04679B1 (xx)
EG (1) EG23999A (xx)
ES (1) ES2175919T3 (xx)
HK (1) HK1031222A1 (xx)
HR (1) HRP20010667B1 (xx)
HU (1) HU229506B1 (xx)
IL (2) IL144958A0 (xx)
IS (1) IS2003B (xx)
ME (2) MEP4008A (xx)
MX (1) MXPA01009081A (xx)
NO (1) NO328363B1 (xx)
NZ (1) NZ513393A (xx)
PE (1) PE20001485A1 (xx)
PL (1) PL222208B1 (xx)
PT (1) PT1044977E (xx)
RS (1) RS50405B (xx)
SI (1) SI1044977T1 (xx)
SK (1) SK287561B6 (xx)
TN (1) TNSN00045A1 (xx)
TR (1) TR200102603T2 (xx)
TW (1) TWI272272B (xx)
WO (1) WO2000053607A1 (xx)
ZA (1) ZA200107408B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370003C (en) 1999-01-13 2008-08-19 Tracey Brown A composition and method for the enhancement of the efficacy of drugs
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
BRPI0509240A (pt) * 2004-03-26 2007-09-04 Novartis Ag regime de tratamento para derivados de camptotecina
EP1744780B1 (en) 2004-04-27 2013-08-07 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
CA2589521C (en) * 2004-12-15 2014-04-01 Novartis Ag Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
KR101355121B1 (ko) 2004-12-21 2014-01-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 캄토테신의 입체선택적 방법 및 결정성 형태
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
AU2006270297B2 (en) 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
WO2007012133A1 (en) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
US20080213385A1 (en) * 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
MY149606A (en) * 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
AU2006328607B2 (en) 2005-12-21 2012-04-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors
WO2007098091A2 (en) 2006-02-17 2007-08-30 Novacea, Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
US20100166843A1 (en) * 2007-02-01 2010-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
EP2120948A1 (en) * 2007-02-13 2009-11-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
SG183010A1 (en) 2007-08-01 2012-08-30 Sigma Tau Ind Farmaceuti Treatment of pediatric tumors
EP2096113A1 (en) * 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
NZ245112A (en) * 1991-11-15 1995-07-26 Smithkline Beecham Corp Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
CN1107678C (zh) * 1996-08-19 2003-05-07 比奥纽默里克药物公司 高亲脂性喜树碱衍生物，其制备方法及其用途

Also Published As

Publication number Publication date
PL355094A1 (en) 2004-03-22
PE20001485A1 (es) 2000-12-07
ES2175919T3 (es) 2002-11-16
JP4610743B2 (ja) 2011-01-12
IS2003B (is) 2005-04-15
BG105810A (en) 2002-06-28
CO5180590A1 (es) 2002-07-30
RS50405B (sr) 2009-12-31
EP1044977A1 (en) 2000-10-18
ME00017B (me) 2010-06-10
EE200100466A (et) 2002-12-16
HUP0200210A3 (en) 2004-03-29
IL144958A (en) 2009-08-03
EP1044977B1 (en) 2002-05-02
EA003605B1 (ru) 2003-06-26
HU229506B1 (en) 2014-01-28
ATE216998T1 (de) 2002-05-15
MEP4008A (xx) 2010-02-10
WO2000053607A1 (en) 2000-09-14
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
MXPA01009081A (es) 2002-08-30
US20010008939A1 (en) 2001-07-19
BR0008840A (pt) 2002-01-08
EG23999A (en) 2008-03-19
AU774174B2 (en) 2004-06-17
DE69901379D1 (de) 2002-06-06
AU3160400A (en) 2000-09-28
HRP20010667A2 (en) 2002-08-31
HK1031222A1 (en) 2001-06-08
EE04679B1 (et) 2006-08-15
CA2362760C (en) 2009-08-18
TWI272272B (en) 2007-02-01
CN1343209A (zh) 2002-04-03
BG65032B1 (bg) 2006-12-29
EA200100954A1 (ru) 2002-04-25
SK287561B6 (sk) 2011-02-04
KR100702085B1 (ko) 2007-04-02
IS6031A (is) 2001-07-31
CN1139592C (zh) 2004-02-25
DE69901379T2 (de) 2002-11-07
PL222208B1 (pl) 2016-07-29
CZ304465B6 (cs) 2014-05-21
SI1044977T1 (en) 2002-08-31
CA2362760A1 (en) 2000-09-14
US6242457B1 (en) 2001-06-05
JP2002539128A (ja) 2002-11-19
YU64301A (sh) 2005-07-19
SK11642001A3 (sk) 2002-01-07
US6589939B2 (en) 2003-07-08
TR200102603T2 (tr) 2002-01-21
AR022860A1 (es) 2002-09-04
NZ513393A (en) 2003-04-29
CZ20013077A3 (cs) 2002-01-16
IL144958A0 (en) 2002-06-30
DK1044977T3 (da) 2002-07-08
NO20014128D0 (no) 2001-08-24
ZA200107408B (en) 2002-05-29
BR0008840B1 (pt) 2011-12-27
KR20010102519A (ko) 2001-11-15
NO20014128L (no) 2001-08-24
TNSN00045A1 (fr) 2005-11-10
HUP0200210A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
EG23999A (en) Camptothecin derivatives having antitumor activity
EG23817A (en) 4-Phenyl-pyridine derivatives
HK1054233A1 (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
IL146100A0 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
GC0000183A (en) 3-Phenyl-pyridine derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
HK1044940A1 (zh) 異噁唑咪唑羧酰胺衍生物
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
HU0003938D0 (en) Quinolin-4-yl derivatives
IL138777A0 (en) Quinolin-4-yl derivatives i
GB0026485D0 (en) ›-Carboline derivatives
HK1048638A1 (zh) Cyclopenteneone衍生物
HK1045987A1 (zh) 3-氨基-2-苄基-1-苯基-丙烷衍生物
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
HK1045698A1 (zh) 阿維菌素衍生物
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
GB0131034D0 (en) Benzocyclodecane derivatives with antitumor activity
GC0000200A (en) Camptothecin derivatives having antitumor activity
AU5769500A (en) Ucf116 derivatives as antitumor agents
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
HK1043987A1 (zh) 硫-羥吲衍生物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170221

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20180308